Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: The 15-min challenge to sort these agents out

International Journal of Clinical Practice

Volumn 68, Issue 12, 2014, Pages 1401-1405

  Citrome, L ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; AMFEBUTAMONE; BENZAZEPINE DERIVATIVE; DRUG COMBINATION; FRUCTOSE; NALTREXONE; PHENTERMINE; TOPIRAMATE;

BACKACHE; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INTERACTION; DRUG PACKAGING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EDITORIAL; EFFECT SIZE; FATIGUE; HEADACHE; HUMAN; HYPOGLYCEMIA; INSOMNIA; LIKELIHOOD TO BE HELPED OR HARMED; MEDICAL DECISION MAKING; NAUSEA; NUMBER NEEDED TO HARM; NUMBER NEEDED TO TREAT; OBESITY; PARAMETERS; PARESTHESIA; PRESCRIPTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS;

BENZAZEPINES; BUPROPION; DRUG COMBINATIONS; DRUG PRESCRIPTIONS; FRUCTOSE; HUMANS; NALTREXONE; OBESITY; PHENTERMINE; WEIGHT LOSS;

EID: 84912049381     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12587     Document Type: Editorial

References (8)

1. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129 (25 Suppl. 2): S102-38.
2. Vincent RP, Le Roux CW,. New agents in development for the management of obesity. Int J Clin Pract 2007; 61: 2103-12.
3. Bray GA,. Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol 2014; 28: 665-84.
4. Arena. BELVIQ (lorcaserin HCl) tablets. Prescribing information. Revised August 2012. http://www.belviqhcp.com/media/1001/belviq-prescribing-information.pdf (accessed 7 October 2014).
5. Vivus. QSYMIA (phentermine and topiramate extended-release) capsules. Revised September 2013. http://qsymia.com/pdf/prescribing-information.pdf (accessed 7 October 2014).
6. Orexigen. CONTRAVE (naltrexone HCl and bupropion HCl) extended-release tablets. Prescribing information. Revised September 2014. http://general.takedapharm.com/content/file.aspx?filetypecode=CONTRAVEPI (accessed 7 October 2014).
7. Citrome L, Ketter TA,. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 2013; 67: 407-11.
8. Genentech. XENICAL (orlistat) capsules. Prescribing information. Revised December 2013. http://www.gene.com/download/pdf/xenical-prescribing.pdf (accessed 13 October 2014).